We believe that a “controlled” infection with a modified version of SARS-CoV-2 along with the administration of IL-6 blockers and PD-L1 checkpoint inhibitors can promote the regression of several different difficult-to-treat aggressive malignancies. This evidence concerns the gene IL6 and infection.